2026 Global: Drug Infusion Systems Market -Competitive Review (2032) report
Description
The 2026 Global: Drug Infusion Systems Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Leading the Drug Infusion Systems Market are multinational manufacturers that supply hospital-grade IV infusion pumps, syringe pumps, and diabetes insulin-delivery devices used to administer drugs, fluids, and biologics with precise dosing. Becton, Dickinson and Company (BD) anchors the segment with the Alaris infusion-pump platform, based in Franklin Lakes, New Jersey, United States, and widely deployed across hospital networks for patient-controlled analgesia and continuous infusion. B. Braun Melsungen AG follows, headquartered in Melsungen, Germany, with Infusomat and Space pump families that support critical care and anesthesia workflows worldwide. Terumo Corporation, headquartered in Tokyo, Japan, offers syringe and infusion pumps under its Terumo brand, leveraging robust Japanese production and global service networks. Fresenius Kabi, based in Bad Homburg vor der Höhe, Germany, markets infusion-solution systems alongside its extensive portfolio of infusion devices and drug-delivery solutions for perioperative and intensive-care settings. ICU Medical, Inc., headquartered in San Clemente, California, United States, focuses on safety-enhanced syringe and peristaltic pumps used in acute care and oncology.
Medtronic plc, headquartered in Dublin, Ireland, extends the infusion-therapy portfolio through MiniMed insulin pumps and related diabetes-management systems that deliver precise, programmable dosing. Smiths Medical, based in London, United Kingdom, supplies syringe and infusion pumps used in critical‑care, anesthesia, and neonatal care, along with dedicated infusion controls. Baxter International Inc., headquartered in Deerfield, Illinois, United States, combines infusion-pump hardware with hospital supply ecosystems to support perioperative and intensive-care workflows across North America and beyond. Nipro Corporation, headquartered in Osaka, Japan, contributes compact syringe- and insulin-pump technologies aligned with its broader diagnostics and medical devices platform, targeting hospital and home settings. Insulet Corporation, headquartered in Acton, Massachusetts, United States, specializes in patch-pump insulin delivery (Omnipod) and allied digital-health tools, capturing a growing segment of diabetes self-management and remote monitoring. Together these firms broaden device coverage across inpatient and outpatient settings, enhancing dosing accuracy, patient safety, and workflow efficiency.
Together, the ten firms above constitute a global core of the Drug Infusion Systems Market, with manufacturing, distribution, and service footprints spanning North America, Europe, and Asia Pacific. Their products address a spectrum of use cases, including inpatient acute-care administration, oncology infusions, pediatric and neonatal care, diabetes therapy, and home-based self-management. Market leadership rests on factors such as product safety, interoperability with electronic medical records, and resilience of global supply chains. Multinational scale enables rapid dissemination of regulatory-compliant devices, while regional manufacturing bases support localized procurement and service continuity. Ongoing investment in connectivity, remote monitoring, and dose-accurate software is accelerating adoption of smart infusion pumps and integrated diabetes-delivery platforms. As clinical practice evolves toward precision dosing and ambulatory care, the roles of these companies will be pivotal to improving patient outcomes, reducing medication errors, and enabling efficient, data-driven care delivery and outcomes.
Leading the Drug Infusion Systems Market are multinational manufacturers that supply hospital-grade IV infusion pumps, syringe pumps, and diabetes insulin-delivery devices used to administer drugs, fluids, and biologics with precise dosing. Becton, Dickinson and Company (BD) anchors the segment with the Alaris infusion-pump platform, based in Franklin Lakes, New Jersey, United States, and widely deployed across hospital networks for patient-controlled analgesia and continuous infusion. B. Braun Melsungen AG follows, headquartered in Melsungen, Germany, with Infusomat and Space pump families that support critical care and anesthesia workflows worldwide. Terumo Corporation, headquartered in Tokyo, Japan, offers syringe and infusion pumps under its Terumo brand, leveraging robust Japanese production and global service networks. Fresenius Kabi, based in Bad Homburg vor der Höhe, Germany, markets infusion-solution systems alongside its extensive portfolio of infusion devices and drug-delivery solutions for perioperative and intensive-care settings. ICU Medical, Inc., headquartered in San Clemente, California, United States, focuses on safety-enhanced syringe and peristaltic pumps used in acute care and oncology.
Medtronic plc, headquartered in Dublin, Ireland, extends the infusion-therapy portfolio through MiniMed insulin pumps and related diabetes-management systems that deliver precise, programmable dosing. Smiths Medical, based in London, United Kingdom, supplies syringe and infusion pumps used in critical‑care, anesthesia, and neonatal care, along with dedicated infusion controls. Baxter International Inc., headquartered in Deerfield, Illinois, United States, combines infusion-pump hardware with hospital supply ecosystems to support perioperative and intensive-care workflows across North America and beyond. Nipro Corporation, headquartered in Osaka, Japan, contributes compact syringe- and insulin-pump technologies aligned with its broader diagnostics and medical devices platform, targeting hospital and home settings. Insulet Corporation, headquartered in Acton, Massachusetts, United States, specializes in patch-pump insulin delivery (Omnipod) and allied digital-health tools, capturing a growing segment of diabetes self-management and remote monitoring. Together these firms broaden device coverage across inpatient and outpatient settings, enhancing dosing accuracy, patient safety, and workflow efficiency.
Together, the ten firms above constitute a global core of the Drug Infusion Systems Market, with manufacturing, distribution, and service footprints spanning North America, Europe, and Asia Pacific. Their products address a spectrum of use cases, including inpatient acute-care administration, oncology infusions, pediatric and neonatal care, diabetes therapy, and home-based self-management. Market leadership rests on factors such as product safety, interoperability with electronic medical records, and resilience of global supply chains. Multinational scale enables rapid dissemination of regulatory-compliant devices, while regional manufacturing bases support localized procurement and service continuity. Ongoing investment in connectivity, remote monitoring, and dose-accurate software is accelerating adoption of smart infusion pumps and integrated diabetes-delivery platforms. As clinical practice evolves toward precision dosing and ambulatory care, the roles of these companies will be pivotal to improving patient outcomes, reducing medication errors, and enabling efficient, data-driven care delivery and outcomes.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
